Investment Thesis
Business model leverages multiple programs to maximize ROI
- Broadly applicable established technology
- Product candidates address multiple therapeutic areas
- Programs address large, underserved patient populations
Development risk can be minimized since the new oral delivery technology is typically applied to “proven” drugs
- Technology is unique in a competitive space
- Does not alter drugs chemically
- Enables practical dosage forms
- Low cost, easy-to-scale EMISPHERE® delivery agents